Follow The Filings

AGIO Agios Pharmaceuticals Inc.

Health Care, filed as AGIOS PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 1.1%
  • $228M
  • 1 add

In 2026 Q2 Farallon Capital Management added to Agios Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 1.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 1.1%
  2. Farallon Capital Management Add 1.0%

Who owns AGIO

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 1.0% Add +4.1% 5,917,400 $220M History
Palo Alto Investors 1.1% Hold 213,601 $7.9M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AGIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AGIO insider trades
  • None no insider bought on the open market
  • $152K sold by 1 insider outside a trading plan
  • $1.4M sold by 2 insiders under 10b5-1 plans
  1. Sarah Gheuens Chief Medical Officer
    Planned sale
    $296K 7,866 shares at $37.69 13% of stake
    Traded Oct 26 Filed Oct 28
    ↗
  2. Sarah Gheuens Chief Medical Officer
    Planned sale
    $75K 1,989 shares at $37.53 3.5% of stake
    Traded Oct 21–22 Filed Oct 23
    ↗
  3. Sarah Gheuens Chief Medical Officer
    Planned sale
    $914K 30,000 shares at $30.48 35% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  4. Theodore James Washburn Jr. Principal Accounting Officer
    Sale
    $152K 5,272 shares at $28.88 86% of stake
    Traded Mar 3 Filed Mar 5
    ↗
  5. David Scadden Director
    Planned sale
    $8,768 200 shares at $43.84 1.1% of stake
    Traded Nov 12, 2025 Filed Nov 14, 2025
    ↗
  6. Sarah Gheuens Chief Medical Officer
    Planned sale
    $107K 2,454 shares at $43.78 3.8% of stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗
  7. Sarah Gheuens Chief Medical Officer
    Planned sale
    $8,762 200 shares at $43.81 0.3% of stake
    Traded Oct 30, 2025 Filed Nov 3, 2025
    ↗
  8. Sarah Gheuens Chief Medical Officer
    Planned sale
    $145K 3,302 shares at $43.92 5.1% of stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗
  9. David Scadden Director
    Planned sale
    $8,200 200 shares at $41.00 1.1% of stake
    Traded Oct 8, 2025 Filed Oct 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 51 option exercises, 35 sales to cover taxes, and 1 stock grant.

Congress

2 members of Congress traded AGIO in the last three years: 6 buys and 0 sales. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Aug 20 filed Sep 10
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Dec 11, 2025 filed Jan 12
  4. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Apr 17, 2025 filed May 6, 2025
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jan 29, 2025 filed Feb 11, 2025
  6. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Jan 24, 2024 filed Feb 15, 2024

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $26.82M $36.5M $54.03M
Gross profit * $23.94M $32.33M $47.68M
Gross margin * 89.3% 88.6% 88.3%
Net income -$352.09M $673.72M -$412.78M
Net margin * -1312.6% 1845.9% -764.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $833.84M $965.6M $942.05M
Total non-current assets * $103.28M $697.6M $355.17M
Total assets $0.937B $1.66B $1.3B
Total current liabilities $67.96M $81.16M $82.21M
Total non-current liabilities * $58.14M $41.09M $21.9M
Total equity $0.811B $1.54B $1.19B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$296.06M -$389.84M -$372.98M
Cash from investing $239.58M $363.44M $377.18M
Cash from financing $5.43M $14.44M $8.68M
Net change in cash -$51.05M -$11.96M $12.88M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.